Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue

Prior treatment

• Any known contraindications to methylphenidate as outlined below:
  • Hypersensitivity to the active substance or any excipients listed in the summary of product characteristics. B) Glaucoma. C) Pheochromocytoma. D) Hyperthyroidism. E) Mania. F) Psychosis. G) Anorexia nervosa. H) Current or previous severe depression. I) Suicidal behavior. J) Poorly controlled type 1 bipolar affective disorder. K) Antisocial or borderline personality disorder. L) Pre-existing cardiovascular disorders, including severe hypertension, heart failure, arterial occlusive disease, angina pectoris, hemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening cardiac arrhythmias and channelopathies. M) Pre-existing cerebrovascular disease, cerebral aneurysm, vascular abnormalities including vasculitis or stroke. N) Treatment with irreversible MAO inhibitors within the last 14 days and reversible MAO inhibitors within the last 24 hours.
• Pregnancy. Participants known to be pregnant or breastfeeding at screening/registration will not be enrolled in the trial. All sexually active women of childbearing potential (WOCBP) must have a negative pregnancy test prior to the start of treatment. Acceptableeffective contraceptive must be used for the duration of the trial. No further testing is needed during trial, unless the participant suspects to have become pregnant.
• Concurrent use of opiods (ATC N02A) or benzodiazepines (ATC N05BA and N05CF).

Other illness

• History of recent poorly controlled seizures.
• Complex tics or Tourette syndrome (including family history of tic disorder).
• Known diagnosis of Attention Deficit/Hyperactivity Disorder or Autism Spectrum Disorder.
• Simultaneously enrolled in another clinical trial investigating cancer-related fatigue with a pharmaceutical intervention.

Other

• Known diagnosis of Full Scale Intelligence Quotient (FSIQ) of \<50.
• Concerns about family ability to safely store or administer MPH, or to report side effects appropriately/concerns about familial substance abuse.

• Diagnosed and treated for a brain tumor during childhood or adolescence (0-≤18 years).
• Treated for a brain tumor during the previous 10 years.
• Age ≥6 years and \<28 years at the start of the trial.
• Off therapy/active treatment for pediatric brain tumor (PBT) for 12 months at the start of the trial.
• No known signs of clinical or radiological tumor progression at last follow-up.
• Danish is the sole or primary language (enabling provision of validated assessment tools).
• Patient and family have provided consent for inclusion in the trial.
• Clinically significant fatigue based on the PedsQL MFS questionnaire at baseline, defined by a score ≥ 1 standard deviation below the normative mean.
• History of clinically relevant fatigue after treatment of PBT compared to estimated premorbid ability, as assessed from consultations in the childhood cancer outpatient clinics.